# **Special Issue**

Understanding New
Therapeutic Options and
Promising Predictive
Biomarkers for Lung Cancer
Patients. A Selection of Papers
from the Third Joint Meeting on
Lung Cancer of the FHU
OncoAge (Nice, France) and the
MD Anderson Cancer Center
(Houston, TX, USA)

## Message from the Guest Editors

Since 2018, FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (MDACC) (Houston, Tx, USA) hosting annual meetings dedicated to recent advances in lung cancer. These meetings were held in person in Nice and then in Houston. This year, on October 4th, the third Joint Meeting on Lung Cancer (JMLC) will be virtually due to COVID-19. This meeting will be coorganized by George Calin, Sendurai Mani and Ignacio Wistuba from the MDACC and by Paul Hofman from the FHU OncoAge. At this third JMLC meeting, experts from the MDACC and for the FHU Oncoage will present the last advances in different fields of thoracic oncology, including new therapeutic options (in targeted therapy and immunotherapy fields), new predictive biomarkers, as well as new discoveries in lung carcinogenesis. The main objective of the Special Issue is to summarize the current trends and discuss different topics. Importantly, this Special Issue will promote understanding of new therapeutic options for lung cancer patients in the near future and decipher the mechanisms of lung carcinoma development and progression.

#### **Guest Editors**

Prof. Dr. Paul Hofman

Prof. Dr. George A. Calin

Dr. Ignacio I. Wistuba

Prof. Dr. Sendurai A. Mani



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/93392

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

